Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Abstract

INTRODUCTION:

The aim of this study was to investigate whe- ther X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum- based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients.

MATERIAL AND METHODS:

From September 2005 to June 2009, 355 advanced-stage NSCLC patients were accrued to compare the SNP variants with the outcome of platinum-based chemotherapy. TaqMan RT-PCR was used to evaluate the SNPs of the XRCC3 codon241 (Thr/Met) and XPD codon751 (Lys/Gln) DNA repair genes.

RESULTS:

There was a lack of association between the studied SNPs and the response rate, progression-free survival or overall survival (OS) in the whole population. However, subgroup analysis revealed that XRCC3 241 Thr/Met or Met/Met allele was associated with marginally significantly longer OS than XRCC3 Thr/Thr allele (19.0 m vs. 12.5 m, p=0.081) in the patients treated with gemcitabine/ cisplatin or carboplatin (GP/GC) while it was correlated with a significantly shorter OS in the patients treated with non GP/GC (9.3 m vs. 16 m, p=0.003). XPD751 Lys/Lys had an association with statistical significantly longer OS than XPD751 Lys/Gln or Gln/Gln in the subgroup of elderly patients (14.10 m vs. 10 m, p=0.019) and patients with non-adenocarcinoma (12.6 m vs. 9 m, p=0.042).

CONCLUSIONS:

XRCC3 Thr241Met played an opposite role in predicting prognosis of chemotherapy in NSCLC patients according to the first-line regimens. XPD 751 Lys/ Lys might be a better prognostic marker of elderly or noncarcinoma NSCLC subgroup treated with platinum-based chemotherapy.

• Authors: Xiaoxia Chen, Hui Sun, Shengxiang Ren, Vikramsingh Kim Curran, Ling Zhang, Songwen Zhou, Jie Zhang, Caicun Zhou
• Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (Clin Transl Oncol) Vol. 14 Issue 3 Pg. 207-13 (Mar 2012) ISSN: 1699-3055 [Electronic] Italy
• PMID: 22374424 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Pharmacological
• Biomarkers, Tumor
• DNA-Binding Proteins
• Platinum Compounds
• X-ray repair cross complementing protein 3
• Xeroderma Pigmentosum Group D Protein
• ERCC2 protein, human

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Pharmacological (metabolism)
• Biomarkers, Tumor (genetics)
• Carcinoma, Non-Small-Cell Lung (diagnosis, drug therapy, genetics, mortality)
• Clinical Trials as Topic
• DNA-Binding Proteins (genetics)
• Disease Progression
• Drug Resistance, Neoplasm (genetics)
• Female
• Genetic Association Studies
• Humans
• Lung Neoplasms (diagnosis, drug therapy, genetics, mortality)
• Male
• Middle Aged
• Platinum Compounds (administration & dosage)
• Polymorphism, Single Nucleotide (physiology)
• Prognosis
• Survival Analysis
• Treatment Outcome
• Xeroderma Pigmentosum Group D Protein (genetics)